Name | BMS-908662 |
---|---|
Synonyms |
UNII:DW2NWI3TFN
Methyl {5-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate BMS-908662 Carbamic acid, N-[5-[2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl]-1H-benzimidazol-2-yl]-, methyl ester DW2NWI3TFN |
Description | XL-281 (BMS 908662) is a potent, selective, orally active inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models; demonstrates biological activity by modulation of the RAF pathway in tumor and surrogate tissue, with decreases in cell proliferation and increases in apoptosis. Colon Cancer Phase 2 Discontinued |
---|---|
References | References 1. Callahan MK, et al. Cancer Immunol Res. 2014 Jan;2(1):70-9. 2. Belum VR, et al. Cancer. 2015 Jan 1;121(1):60-8. 3. Dickson MA, et al. Invest New Drugs. 2015 Apr;33(2):349-56. View Related Products by Target Raf Colon Cancer |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C24H19ClN4O4 |
Molecular Weight | 462.885 |
Exact Mass | 462.109497 |
LogP | 5.03 |
Index of Refraction | 1.754 |